GOVX vs. GNTA, MCRB, OKYO, IKNA, STRO, MNOV, ANRO, PYRGF, INCR, and VTGN
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Genenta Science (GNTA), Seres Therapeutics (MCRB), OKYO Pharma (OKYO), Ikena Oncology (IKNA), Sutro Biopharma (STRO), MediciNova (MNOV), Alto Neuroscience (ANRO), PyroGenesis Canada (PYRGF), InterCure (INCR), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs.
GeoVax Labs (NASDAQ:GOVX) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 1.2% of GeoVax Labs shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Genenta Science had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 5 mentions for Genenta Science and 4 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.96 beat Genenta Science's score of 0.96 indicating that GeoVax Labs is being referred to more favorably in the media.
GeoVax Labs has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
GeoVax Labs received 23 more outperform votes than Genenta Science when rated by MarketBeat users. Likewise, 96.77% of users gave GeoVax Labs an outperform vote while only 87.50% of users gave Genenta Science an outperform vote.
Genenta Science's return on equity of 0.00% beat GeoVax Labs' return on equity.
Genenta Science has lower revenue, but higher earnings than GeoVax Labs.
GeoVax Labs presently has a consensus target price of $11.10, indicating a potential upside of 873.68%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 554.45%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts clearly believe GeoVax Labs is more favorable than Genenta Science.
Summary
GeoVax Labs beats Genenta Science on 9 of the 15 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy GOVX Stock Free GOVX Stock Alerts